Drug Trial Radar · NCT05153330
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Last checked: Nov 19, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
55
Actual
Start
Jan 24, 2022
Primary completion
Feb 13, 2025
Study completion May 2, 2025
Sponsor
- Lead sponsor
- Biomea Fusion Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
Conditions
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Acute Mixed-Phenotype Leukemia
- Cancer
- Refractory
- Progression
- Diffuse Large B Cell Lymphoma
- Multiple Myeloma
- Lymphoma
- Lymphoma, Non-Hodgkin
- Myeloma, Plasma-Cell
- Myelomatosis
- Plasma Cell Myeloma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
BMF-219Drug
BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine Optimal Biologic Dose (OBD) and RP2D of BMF-219 monotherapy for (Cohorts 1, 2, 3 & 4)Time frame: At the end of Cycle 1 (each Cycle is 28 Days in duration)
Locations
41 sites in 5 countries. Site status is shown where the registry gives one.
University of California, Irvine
Irvine, California
University of Southern California Norris Cancer Center
Los Angeles, California
UCLA Department of Medicine
Los Angeles, California
UC Davis Comprehensive Cancer Center
Sacramento, California
Stanford Cancer Center
Stanford, California
Mayo Clinic
Jacksonville, Florida
Mount Sinai Medical Center
Miami Beach, Florida
Moffitt Cancer Center
Tampa, Florida
Blood & Marrow Transplant Group of GA (Northside Hospital)
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Henry Ford Hospital
Detroit, Michigan
University of Cincinnati Medical Center
Cincinnati, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Vanderbilt University Medical Center
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists
Gainesville, Virginia
Evangelismos General Hospital of Athens
Athens, Greece
Alexandra General Hospital of Athens
Athens, Greece
AOU Ospedali Riuniti Ancona
Ancona, Italy
ASST Papa Giovanni XXIII Hospital Bergamo
Bergamo, Italy
Instituto Clinico Humanitas
Milan, Italy
IRCCS Ospedale San Raffaele, Programma di Ricerca Strategica su LLC
Milan, Italy
Istituto Europeo di Oncologia
Milan, Italy
Ospedale Santa Maria della Misericordia
Perugia, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
Amsterdam UMC
Amsterdam, Netherlands
UMCG Groningen
Groningen, Netherlands
Radboud University Medical Center
Nijmegen, Netherlands
Erasmus University Medical Center Rotterdam
Rotterdam, Netherlands
Hospital General de Albacete
Albacete, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Institut Catala d'Oncologia
Barcelona, Spain
Hospital San Pedro de Alcántara
Cáceres, Spain
Hospital Universitario de la Princesa
Madrid, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Central de Asturias
Oviedo, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.